STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. 

Up until last year, CREATE was known as Myeloid Therapeutics. The startup was cofounded by noted writer and oncologist Siddhartha Mukherjee to develop better CAR-T therapies using a type of immune agent called myeloid cells, ideally to better attack solid tumors. The company rebranded last fall and, like many other oncology CAR-T companies, expanded into autoimmune disease research. 

Now, CREATE has raised another $122 million from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and others, the biotech told STAT exclusively.

Continue to STAT+ to read the full story…